FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890894218> ?p ?o ?g. }

• W2890894218 abstract "e15018 Background: Controversy surrounds the question of whether the prognosis of most patients with metastatic colorectal cancer (mCRC) is improved using intensive administration of folinic acid, 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) alone or combined with target therapy as first-line treatment. Methods: We queried PubMed, the Cochrane Collaboration Central Register of Controlled Clinical Trials, Cochrane Systematic Reviews, ClinicalTrials.gov, the databases of the European Society for Medical Oncology and the American Society of Clinical Oncology to identify abstracts of randomized controlled trials evaluating the efficacies and toxicities of intensive therapies used for first-line treatment of patients with mCRC. The search included articles dated from the inception of these resources until December 31, 2016. We estimated hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) and relative risks (RRs) for the objective response rate (ORR), the R0 resection rate, and toxicities. Results: Nine RCTs comprising 2,256 patients were included in this network meta-analysis. The PFS of patients administered FOLFOXIRI plus target therapy experienced prolonged PFS and OS and improved ORRs compared with FOLFOX or FOLFIRI plus target therapy (PFS: HR 0.65, 95% CI 0.46–0.91; OS: HR 0.80, 95% CI 0.65–0.98; ORR: HR 1.70, 95% CI 1.16–2.49; R0 resection rate: HR 2.66, 95% CI 1.86–3.82). There were no significant differences between PFS, OS, ORRs, or R0 resection rates and toxicities of patients administered FOLFOXIRI and FOLFOX or FOLFIRI plus target therapy. Further, FOLFOXIRI plus target therapy did not increase toxicities compared with FOLFOX or FOLFIRI plus target therapy, except for neutropenia. Conclusions: FOLFOXIRI plus target therapy when administered as first-line treatment of patients with mCRC is the best choice and did not significantly increase toxicities. FOLFOXIRI is as effective as FOLFOX or FOLFIRI plus target therapy." @default.
• W2890894218 created "2018-09-27" @default.
• W2890894218 creator A5010072636 @default.
• W2890894218 creator A5029395960 @default.
• W2890894218 creator A5042325222 @default.
• W2890894218 creator A5044569242 @default.
• W2890894218 creator A5065153516 @default.
• W2890894218 creator A5071149622 @default.
• W2890894218 creator A5083245206 @default.
• W2890894218 date "2017-05-20" @default.
• W2890894218 modified "2023-09-26" @default.
• W2890894218 title "Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis." @default.
• W2890894218 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e15018" @default.
• W2890894218 hasPublicationYear "2017" @default.
• W2890894218 type Work @default.
• W2890894218 sameAs 2890894218 @default.
• W2890894218 citedByCount "0" @default.
• W2890894218 crossrefType "journal-article" @default.
• W2890894218 hasAuthorship W2890894218A5010072636 @default.
• W2890894218 hasAuthorship W2890894218A5029395960 @default.
• W2890894218 hasAuthorship W2890894218A5042325222 @default.
• W2890894218 hasAuthorship W2890894218A5044569242 @default.
• W2890894218 hasAuthorship W2890894218A5065153516 @default.
• W2890894218 hasAuthorship W2890894218A5071149622 @default.
• W2890894218 hasAuthorship W2890894218A5083245206 @default.
• W2890894218 hasConcept C126322002 @default.
• W2890894218 hasConcept C143998085 @default.
• W2890894218 hasConcept C71924100 @default.
• W2890894218 hasConcept C95190672 @default.
• W2890894218 hasConceptScore W2890894218C126322002 @default.
• W2890894218 hasConceptScore W2890894218C143998085 @default.
• W2890894218 hasConceptScore W2890894218C71924100 @default.
• W2890894218 hasConceptScore W2890894218C95190672 @default.
• W2890894218 hasLocation W28908942181 @default.
• W2890894218 hasOpenAccess W2890894218 @default.
• W2890894218 hasPrimaryLocation W28908942181 @default.
• W2890894218 hasRelatedWork W2121830614 @default.
• W2890894218 hasRelatedWork W2322488193 @default.
• W2890894218 hasRelatedWork W2471542599 @default.
• W2890894218 hasRelatedWork W2517793684 @default.
• W2890894218 hasRelatedWork W2526890366 @default.
• W2890894218 hasRelatedWork W2590360874 @default.
• W2890894218 hasRelatedWork W2590595488 @default.
• W2890894218 hasRelatedWork W2590680924 @default.
• W2890894218 hasRelatedWork W2597629258 @default.
• W2890894218 hasRelatedWork W2600084901 @default.
• W2890894218 hasRelatedWork W2622186675 @default.
• W2890894218 hasRelatedWork W2749779586 @default.
• W2890894218 hasRelatedWork W2891089767 @default.
• W2890894218 hasRelatedWork W2894967395 @default.
• W2890894218 hasRelatedWork W3005232660 @default.
• W2890894218 hasRelatedWork W3029741075 @default.
• W2890894218 hasRelatedWork W3030739193 @default.
• W2890894218 hasRelatedWork W3166456074 @default.
• W2890894218 hasRelatedWork W3198422742 @default.
• W2890894218 hasRelatedWork W2909787771 @default.
• W2890894218 isParatext "false" @default.
• W2890894218 isRetracted "false" @default.
• W2890894218 magId "2890894218" @default.
• W2890894218 workType "article" @default.